Baidu
map

前列腺癌:单次活检不足以指导治疗

2016-10-02 薄荷 生物通

尽管大多数前列腺癌进展缓慢,并无大碍,但仍有30%的前列腺癌却是致命的。基因组图谱可帮助预测肿瘤的侵略性,并量身定制治疗方案,然而,在大多数涉及到多个肿瘤的癌症病例中,只有最大的肿瘤才被分析,这可能导致更多的侵略性肿瘤未被发现。在《European Urology》杂志近期发表的一篇文章中,克利夫兰诊所的Hannelore Heemers博士和Roswell Park癌症研究所的James Moh

尽管大多数前列腺癌进展缓慢,并无大碍,但仍有30%的前列腺癌却是致命的。基因组图谱可帮助预测肿瘤的侵略性,并量身定制治疗方案,然而,在大多数涉及到多个肿瘤的癌症病例中,只有最大的肿瘤才被分析,这可能导致更多的侵略性肿瘤未被发现。

在《European Urology》杂志近期发表的一篇文章中,克利夫兰诊所的Hannelore Heemers博士和Roswell Park癌症研究所的James Mohler博士证明,当基因组指纹图谱分析只在单个肿瘤样本上开展时,一些更小但更具侵略性的肿瘤可能被错过。

这项研究强调了,对于前列腺癌,每位患者在遗传上也许都是不同的,这对患者和肿瘤医生而言具有重要的意义。

在这项研究中,研究小组利用新一代测序技术对四名男性的前列腺肿瘤进行基因分型,这些患者在Roswell Park癌症研究所进行了根治性的前列腺切除手术。他们对样本开展全外显子组测序、单核苷酸多态性分析以及RNA测序。同时,研究人员还查看了癌症基因组图谱中的公开数据,以验证他们的结果。

“通过DNA和RNA分析平台,我们研究了前列腺患者异质性肿瘤的分子组成,并发现这些肿瘤之间存在很多遗传差异。因此,我们的结论是,单次癌症活检不足以指导治疗决策,”Heemers博士谈道。“精准治疗更加复杂,目前的研究结果证明了遗传图谱分析在前列腺癌中的不足。”

Mohler博士认为,高风险的前列腺癌在遗传上因人而异,即使是同一位患者的不同肿瘤,甚至同一个肿瘤的不同部位,也存在差异。“临床医生需要谨慎使用基因检测的信息,因为这些分析可能不是在最具侵略性的部位上开展的。”

在发表于同一杂志上的社论文章中,剑桥大学医院的Alastair David Lamb博士等人写道:“这项研究的几个方面令人印象深刻。作者们解决了一个重要的临床和分子问题:肿瘤异质性对前列腺癌的治疗决策有何影响,特别是这种疾病的分子分类?”

他们指出,利用基因组分析来实现个性化治疗正处于起步阶段,还需要更多的大型研究,才能开发出新一代的预后工具,并依靠它来指导前列腺癌患者的疗法选择。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (14)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=152995, encodeId=ecbe15299517, content=对于前列腺癌,每位患者在遗传上也许都是不同的,这对患者和肿瘤医生而言具有重要的意义。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160903/IMG57CA05C7ADAC62159.jpg, createdBy=ea6c1943408, createdName=镱鉎鉌釚, createdTime=Thu Nov 03 00:03:51 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145377, encodeId=93201453e744, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 20:17:26 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=143097, encodeId=c15614309e10, content=文章很好,继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 10 10:58:46 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139728, encodeId=ab4f139e28b1, content=这为肿瘤个体化提供了借鉴, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a431926374, createdName=1e0bc67dm33(暂无匿称), createdTime=Tue Oct 04 06:34:45 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277986, encodeId=ebc012e798680, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Tue Oct 04 00:27:00 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139605, encodeId=2f5e1396051d, content=总结的很好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Mon Oct 03 16:46:26 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139604, encodeId=4dd113960408, content=学习了,分享一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Mon Oct 03 16:46:19 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139181, encodeId=e4cb1391819f, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Oct 02 22:45:21 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139123, encodeId=cd5913912365, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Oct 02 17:52:48 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139122, encodeId=5a9213912213, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Oct 02 17:52:42 CST 2016, time=2016-10-02, status=1, ipAttribution=)]
    2016-11-03 镱鉎鉌釚

    对于前列腺癌,每位患者在遗传上也许都是不同的,这对患者和肿瘤医生而言具有重要的意义。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=152995, encodeId=ecbe15299517, content=对于前列腺癌,每位患者在遗传上也许都是不同的,这对患者和肿瘤医生而言具有重要的意义。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160903/IMG57CA05C7ADAC62159.jpg, createdBy=ea6c1943408, createdName=镱鉎鉌釚, createdTime=Thu Nov 03 00:03:51 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145377, encodeId=93201453e744, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 20:17:26 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=143097, encodeId=c15614309e10, content=文章很好,继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 10 10:58:46 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139728, encodeId=ab4f139e28b1, content=这为肿瘤个体化提供了借鉴, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a431926374, createdName=1e0bc67dm33(暂无匿称), createdTime=Tue Oct 04 06:34:45 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277986, encodeId=ebc012e798680, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Tue Oct 04 00:27:00 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139605, encodeId=2f5e1396051d, content=总结的很好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Mon Oct 03 16:46:26 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139604, encodeId=4dd113960408, content=学习了,分享一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Mon Oct 03 16:46:19 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139181, encodeId=e4cb1391819f, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Oct 02 22:45:21 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139123, encodeId=cd5913912365, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Oct 02 17:52:48 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139122, encodeId=5a9213912213, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Oct 02 17:52:42 CST 2016, time=2016-10-02, status=1, ipAttribution=)]
    2016-10-11 1e10c84am36(暂无匿称)

    好文章,受益

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=152995, encodeId=ecbe15299517, content=对于前列腺癌,每位患者在遗传上也许都是不同的,这对患者和肿瘤医生而言具有重要的意义。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160903/IMG57CA05C7ADAC62159.jpg, createdBy=ea6c1943408, createdName=镱鉎鉌釚, createdTime=Thu Nov 03 00:03:51 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145377, encodeId=93201453e744, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 20:17:26 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=143097, encodeId=c15614309e10, content=文章很好,继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 10 10:58:46 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139728, encodeId=ab4f139e28b1, content=这为肿瘤个体化提供了借鉴, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a431926374, createdName=1e0bc67dm33(暂无匿称), createdTime=Tue Oct 04 06:34:45 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277986, encodeId=ebc012e798680, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Tue Oct 04 00:27:00 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139605, encodeId=2f5e1396051d, content=总结的很好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Mon Oct 03 16:46:26 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139604, encodeId=4dd113960408, content=学习了,分享一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Mon Oct 03 16:46:19 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139181, encodeId=e4cb1391819f, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Oct 02 22:45:21 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139123, encodeId=cd5913912365, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Oct 02 17:52:48 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139122, encodeId=5a9213912213, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Oct 02 17:52:42 CST 2016, time=2016-10-02, status=1, ipAttribution=)]
    2016-10-10 1e10c84am36(暂无匿称)

    文章很好,继续关注

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=152995, encodeId=ecbe15299517, content=对于前列腺癌,每位患者在遗传上也许都是不同的,这对患者和肿瘤医生而言具有重要的意义。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160903/IMG57CA05C7ADAC62159.jpg, createdBy=ea6c1943408, createdName=镱鉎鉌釚, createdTime=Thu Nov 03 00:03:51 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145377, encodeId=93201453e744, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 20:17:26 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=143097, encodeId=c15614309e10, content=文章很好,继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 10 10:58:46 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139728, encodeId=ab4f139e28b1, content=这为肿瘤个体化提供了借鉴, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a431926374, createdName=1e0bc67dm33(暂无匿称), createdTime=Tue Oct 04 06:34:45 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277986, encodeId=ebc012e798680, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Tue Oct 04 00:27:00 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139605, encodeId=2f5e1396051d, content=总结的很好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Mon Oct 03 16:46:26 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139604, encodeId=4dd113960408, content=学习了,分享一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Mon Oct 03 16:46:19 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139181, encodeId=e4cb1391819f, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Oct 02 22:45:21 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139123, encodeId=cd5913912365, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Oct 02 17:52:48 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139122, encodeId=5a9213912213, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Oct 02 17:52:42 CST 2016, time=2016-10-02, status=1, ipAttribution=)]
    2016-10-04 1e0bc67dm33(暂无匿称)

    这为肿瘤个体化提供了借鉴

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=152995, encodeId=ecbe15299517, content=对于前列腺癌,每位患者在遗传上也许都是不同的,这对患者和肿瘤医生而言具有重要的意义。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160903/IMG57CA05C7ADAC62159.jpg, createdBy=ea6c1943408, createdName=镱鉎鉌釚, createdTime=Thu Nov 03 00:03:51 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145377, encodeId=93201453e744, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 20:17:26 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=143097, encodeId=c15614309e10, content=文章很好,继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 10 10:58:46 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139728, encodeId=ab4f139e28b1, content=这为肿瘤个体化提供了借鉴, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a431926374, createdName=1e0bc67dm33(暂无匿称), createdTime=Tue Oct 04 06:34:45 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277986, encodeId=ebc012e798680, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Tue Oct 04 00:27:00 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139605, encodeId=2f5e1396051d, content=总结的很好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Mon Oct 03 16:46:26 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139604, encodeId=4dd113960408, content=学习了,分享一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Mon Oct 03 16:46:19 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139181, encodeId=e4cb1391819f, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Oct 02 22:45:21 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139123, encodeId=cd5913912365, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Oct 02 17:52:48 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139122, encodeId=5a9213912213, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Oct 02 17:52:42 CST 2016, time=2016-10-02, status=1, ipAttribution=)]
    2016-10-04 smlt2008
  6. [GetPortalCommentsPageByObjectIdResponse(id=152995, encodeId=ecbe15299517, content=对于前列腺癌,每位患者在遗传上也许都是不同的,这对患者和肿瘤医生而言具有重要的意义。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160903/IMG57CA05C7ADAC62159.jpg, createdBy=ea6c1943408, createdName=镱鉎鉌釚, createdTime=Thu Nov 03 00:03:51 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145377, encodeId=93201453e744, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 20:17:26 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=143097, encodeId=c15614309e10, content=文章很好,继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 10 10:58:46 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139728, encodeId=ab4f139e28b1, content=这为肿瘤个体化提供了借鉴, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a431926374, createdName=1e0bc67dm33(暂无匿称), createdTime=Tue Oct 04 06:34:45 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277986, encodeId=ebc012e798680, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Tue Oct 04 00:27:00 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139605, encodeId=2f5e1396051d, content=总结的很好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Mon Oct 03 16:46:26 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139604, encodeId=4dd113960408, content=学习了,分享一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Mon Oct 03 16:46:19 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139181, encodeId=e4cb1391819f, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Oct 02 22:45:21 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139123, encodeId=cd5913912365, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Oct 02 17:52:48 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139122, encodeId=5a9213912213, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Oct 02 17:52:42 CST 2016, time=2016-10-02, status=1, ipAttribution=)]
    2016-10-03 1e0d99ddm02(暂无匿称)

    总结的很好!

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=152995, encodeId=ecbe15299517, content=对于前列腺癌,每位患者在遗传上也许都是不同的,这对患者和肿瘤医生而言具有重要的意义。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160903/IMG57CA05C7ADAC62159.jpg, createdBy=ea6c1943408, createdName=镱鉎鉌釚, createdTime=Thu Nov 03 00:03:51 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145377, encodeId=93201453e744, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 20:17:26 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=143097, encodeId=c15614309e10, content=文章很好,继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 10 10:58:46 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139728, encodeId=ab4f139e28b1, content=这为肿瘤个体化提供了借鉴, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a431926374, createdName=1e0bc67dm33(暂无匿称), createdTime=Tue Oct 04 06:34:45 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277986, encodeId=ebc012e798680, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Tue Oct 04 00:27:00 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139605, encodeId=2f5e1396051d, content=总结的很好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Mon Oct 03 16:46:26 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139604, encodeId=4dd113960408, content=学习了,分享一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Mon Oct 03 16:46:19 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139181, encodeId=e4cb1391819f, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Oct 02 22:45:21 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139123, encodeId=cd5913912365, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Oct 02 17:52:48 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139122, encodeId=5a9213912213, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Oct 02 17:52:42 CST 2016, time=2016-10-02, status=1, ipAttribution=)]
    2016-10-03 1e0d99ddm02(暂无匿称)

    学习了,分享一下!

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=152995, encodeId=ecbe15299517, content=对于前列腺癌,每位患者在遗传上也许都是不同的,这对患者和肿瘤医生而言具有重要的意义。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160903/IMG57CA05C7ADAC62159.jpg, createdBy=ea6c1943408, createdName=镱鉎鉌釚, createdTime=Thu Nov 03 00:03:51 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145377, encodeId=93201453e744, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 20:17:26 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=143097, encodeId=c15614309e10, content=文章很好,继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 10 10:58:46 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139728, encodeId=ab4f139e28b1, content=这为肿瘤个体化提供了借鉴, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a431926374, createdName=1e0bc67dm33(暂无匿称), createdTime=Tue Oct 04 06:34:45 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277986, encodeId=ebc012e798680, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Tue Oct 04 00:27:00 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139605, encodeId=2f5e1396051d, content=总结的很好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Mon Oct 03 16:46:26 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139604, encodeId=4dd113960408, content=学习了,分享一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Mon Oct 03 16:46:19 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139181, encodeId=e4cb1391819f, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Oct 02 22:45:21 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139123, encodeId=cd5913912365, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Oct 02 17:52:48 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139122, encodeId=5a9213912213, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Oct 02 17:52:42 CST 2016, time=2016-10-02, status=1, ipAttribution=)]
    2016-10-02 忠诚向上

    好好学习

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=152995, encodeId=ecbe15299517, content=对于前列腺癌,每位患者在遗传上也许都是不同的,这对患者和肿瘤医生而言具有重要的意义。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160903/IMG57CA05C7ADAC62159.jpg, createdBy=ea6c1943408, createdName=镱鉎鉌釚, createdTime=Thu Nov 03 00:03:51 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145377, encodeId=93201453e744, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 20:17:26 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=143097, encodeId=c15614309e10, content=文章很好,继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 10 10:58:46 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139728, encodeId=ab4f139e28b1, content=这为肿瘤个体化提供了借鉴, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a431926374, createdName=1e0bc67dm33(暂无匿称), createdTime=Tue Oct 04 06:34:45 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277986, encodeId=ebc012e798680, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Tue Oct 04 00:27:00 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139605, encodeId=2f5e1396051d, content=总结的很好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Mon Oct 03 16:46:26 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139604, encodeId=4dd113960408, content=学习了,分享一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Mon Oct 03 16:46:19 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139181, encodeId=e4cb1391819f, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Oct 02 22:45:21 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139123, encodeId=cd5913912365, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Oct 02 17:52:48 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139122, encodeId=5a9213912213, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Oct 02 17:52:42 CST 2016, time=2016-10-02, status=1, ipAttribution=)]
    2016-10-02 doctorJiangchao

    继续关注

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=152995, encodeId=ecbe15299517, content=对于前列腺癌,每位患者在遗传上也许都是不同的,这对患者和肿瘤医生而言具有重要的意义。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160903/IMG57CA05C7ADAC62159.jpg, createdBy=ea6c1943408, createdName=镱鉎鉌釚, createdTime=Thu Nov 03 00:03:51 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145377, encodeId=93201453e744, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 20:17:26 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=143097, encodeId=c15614309e10, content=文章很好,继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 10 10:58:46 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139728, encodeId=ab4f139e28b1, content=这为肿瘤个体化提供了借鉴, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a431926374, createdName=1e0bc67dm33(暂无匿称), createdTime=Tue Oct 04 06:34:45 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277986, encodeId=ebc012e798680, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Tue Oct 04 00:27:00 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139605, encodeId=2f5e1396051d, content=总结的很好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Mon Oct 03 16:46:26 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139604, encodeId=4dd113960408, content=学习了,分享一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Mon Oct 03 16:46:19 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139181, encodeId=e4cb1391819f, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Oct 02 22:45:21 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139123, encodeId=cd5913912365, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Oct 02 17:52:48 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139122, encodeId=5a9213912213, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Oct 02 17:52:42 CST 2016, time=2016-10-02, status=1, ipAttribution=)]
    2016-10-02 doctorJiangchao

    继续学习

    0

相关资讯

Cancer:去势耐受性前列腺癌患者肝和/或肺转移后接受enzalutamid治疗效果更好

背景:去势耐受性(抵抗性)前列腺癌CRPC的定义:经过初次持续性内分泌治疗后疾病依然进展的前列腺癌,同时具备:(1)血清睾酮达到去势水平(小于50ng/dl或小于1.7nmol/L)(2)间隔一周,连续3次PSA上升,较最低值升高50%以上。可以这么认为,这样的患者一定是接受了内分泌治疗,可以是单纯的抗雄治疗,也可以是单纯的去雄治疗,也可以是联合应用,但一定是持续性内分泌治疗;疾病进展包括症状的出

CCR:新研究在CTC中发现与前列腺癌治疗抵抗有关的标记物

来自美国杜克癌症研究所的研究人员一直在寻找一种非侵入性方式来检测血液中循环的前列腺癌细胞,在这一过程中他们发现了一些与肿瘤抵抗激素治疗有关的血液标记物。这项研究发表在国际学术期刊Clinical Cancer Research上。该研究报道称他们利用一种新技术在循环的前列腺肿瘤细胞中发现多个关键基因的变化,参与研究的这些病人已经对阿比特龙(一种雄激素拮抗药)和恩扎鲁胺这两种药物的治疗产生抵抗。恩扎

ASTRO 2016:中危前列腺癌患者接受近距离放疗就足够了

ASTRO年会上的数据显示:对于中度风险前列腺癌患者,近距离放射治疗基础上添加外照射治疗,并不能显著延长患者的无进展生存期。因此,只需要短距离放射治疗就能为这一类人群提供足够的癌症控制,并且长期不良事件更少。 德保罗医疗中心的Bradley Prestidge博士和同事们假设,中危前列腺癌患者在短距离放射治疗基础上添加外照射治疗、或组织植入放射性粒子,以周围健康组织的限制辐射暴露,与仅仅接受

ASTRO 2016:极大分割放疗和常规放疗治疗前列腺癌,毒性相当

ASTRO年会上的一项随机、开放标签、3期试验的早期毒性分析数据显示:对于中危前列腺癌患者,极大分割放疗与常规放疗相比,2年后的不良事件发生情况相似。 来自瑞典Umeå大学的Anders Widmark博士和同事们对1200例中度风险前列腺癌患者进行了研究,关于极大分割放疗和常规放疗的非劣效性试验。 患者被随机分到常规分次放疗(中位数78 Gy),超过8周的时间,7次疗程;或者极大分割

2016NCCN临床实践指南——前列腺癌(2016.V3)发布

2016年5月,美国国家综合癌症网络(NCCN)发布前列腺癌指南2016年第3版,指南更新摘要如下:初始前列腺癌诊断非常低风险:初始治疗、辅助治疗低风险:初始治疗、辅助治疗中间风险:初始治疗、辅助治疗高风险,极高风险:初始治疗、辅助治疗检测,复发前列腺切除术失败放射治疗复发系统治疗随后系统治疗生存寿命评估原则影像检查原则积极监测和观察原则放射治疗原则手术治疗原则雄激素剥夺疗法的原则免疫治疗和化疗的

Cancer:[综述]前列腺癌的免疫治疗——海市辰楼or明日之星?

前列腺癌(PCa)是男性的第二大肿瘤,发达国家前列腺患者约有  15%,其病率要略高于欠发达区,其死亡率位居第五,但是前列腺癌的早期筛查和处理极具挑战。在过去的十年里,大量可信度较高的证据显示前列腺癌是免疫性相关的,前列腺内存在的一些肿瘤相关性抗原进一步证实了它的可行性,这些抗原主要有 PSA、前列腺酸性磷酸酶(PAP)、前列腺特异性膜抗原(PSMA)、前列腺肝细胞抗原(PSCA)、粘蛋

Baidu
map
Baidu
map
Baidu
map